Valuation: Northwest Biotherapeutics, Inc.

Market Cap 282M 246M 232M 211M 395M 27.09B 397M 2.78B 1.07B 13.77B 1.06B 1.04B 44.31B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 378M 330M 312M 283M 530M 36.31B 532M 3.73B 1.44B 18.46B 1.42B 1.39B 59.39B EV / Sales 2026 *
-
EV / Sales 2027 * 10.5x
Free-Float
95.22%
Yield 2026 *
-
Yield 2027 * -
08-15 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-07 Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration CI
07-09 Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma CI
05-16 Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-21 Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic CI
04-16 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-15 Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
11-15 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-14 Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP CI
01/11/25 Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC CI
27/10/25 Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding CI
24/10/25 Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC. CI
27/08/25 Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million. CI
1 day-3.26%
1 week-3.12%
Current month-5.92%
1 month-12.27%
3 months-15.76%
6 months-19.95%
Current year-30.01%
1 week 0.16
Extreme 0.1581
0.18
1 month 0.16
Extreme 0.1581
0.22
Current year 0.14
Extreme 0.1411
0.34
1 year 0.14
Extreme 0.1411
0.34
3 years 0.14
Extreme 0.1411
1.09
5 years 0.14
Extreme 0.1411
2.05
10 years 0.14
Extreme 0.14
2.51
Manager TitleAgeSince
Chief Executive Officer 82 01/06/2007
Chief Executive Officer 71 08/06/2011
Chief Tech/Sci/R&D Officer 67 01/01/2000
Director TitleAgeSince
Director/Board Member 82 01/01/1998
Chairman 71 17/05/2007
Director/Board Member 57 01/04/2012
Date Insider Type Main position Quantity % Market Cap. Importance
29/8/24 Don

Founder

1,000,000 0.0826%
9/8/24 Don

Chief Technology Officer

3,000,000 0.2478%
8/8/24 Don

Founder

1,000,000 0.0826%
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%-3.12%-36.49%-76.68% 282M
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+1.82%+38.93%+77.73% 62.32B
-3.21%-5.72%-17.12%+350.96% 27.07B
-2.64%-0.35%-2.13%-15.04% 24.78B
+0.71%+8.50%+27.76%-15.29% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.22%+1.62%+44.31%+167.58% 14.49B
+0.73%+5.00%-1.33%+854.55% 14.14B
-0.54%-0.30%+27.33%+202.19% 12.35B
Average -0.96%+1.53%+29.84%+193.70% 26.24B
Weighted average by Cap. -0.59%+1.39%+35.71%+161.08%

Financials

2026 *2027 *
Net sales - 38.93M 33.95M 32.06M 29.11M 54.54M 3.74B 54.77M 384M 148M 1.9B 146M 143M 6.11B
Net income - -
Net Debt 96.08M 83.78M 79.11M 71.84M 135M 9.22B 135M 948M 366M 4.69B 361M 353M 15.08B 125M 109M 103M 93.41M 175M 11.99B 176M 1.23B 476M 6.1B 469M 459M 19.61B
Logo Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.
Employees
105
Date Price Change Volume
19/09/26 US$0.1601 -3.26% 4,589,657
17/09/26 US$0.1655 -0.05% 1,260,941
16/09/26 US$0.1656 -3.78% 1,941,472
15/09/26 US$0.1721 +4.43% 1,814,895
14/09/26 US$0.1648 -2.43% 1,449,818
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1601USD
Average target price
1.000USD
Spread / Average Target
+524.61%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NWBO Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!